Clinical trials: Advanced Adenocarcinoma
Advanced Pancreatic Ductal Adenocarcinoma
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1.
- Trial name
- NCT06825546
- Testing
- Icaritin, AG chemotherapy
- Where
- 6 sites in China
- Volunteers
- 70 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Hepatocellular Carcinoma
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
The aim of this study is to compare the efficacy of conventional transarterial chemoembolization(TACE) and transarterial radioembolization in patients with unilobar advanced hepatocellular carcinoma.
- Trial name
- NCT02004210
- Testing
- transarterial radioembolization (TARE), transarterial chemoembolization (TACE)
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Carcinoma, Pancreatic Ductal
Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy or in combination with capecitabine or…
- Trial name
- NCT01394120
- Testing
- Targeted Therapy Tailored Treatment, Standard Chemotherapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Sofia Perea, Director Clinical Trials Unit.
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Hepatocellular Carcinoma
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
- Trial name
- NCT04297280
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Cervical Cancer
Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276796
- Testing
- cisplatin, paclitaxel, topotecan hydrochloride
- Volunteers
- 66 people
- Sponsor
- Gynecologic Oncology Group
Renal Cell Cancer, Advanced Renal Cell Cancer
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in…
- Trial name
- UroRCC (NCT02429440)
- Testing
- peptide vaccine, Granulocyte Macrophage Colony Stimulating Factor, Montanide ISA-51
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
Gastric Adenocarcinoma
Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma
Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A cure rate is improving due to early diagnosis.
- Trial name
- NCT03814759
- Testing
- TS-1 + cisplatin, radiation
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Yonsei University
Pancreatic Cancer
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC…
- Trial name
- NCT06378580
- Testing
- Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Luo Cong
Biliary Tract Adenocarcinoma
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase…
- Trial name
- NCT05350943
- Testing
- HAIC, Gemcitabine, Oxaliplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lu Wang, MD, PhD
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT04821284
- Testing
- Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil
- Where
- 2 sites in United States, Norway
- Volunteers
- 120 people
- Sponsor
- Flemming Forsberg
Hepatocellular Carcinoma
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for…
- Trial name
- NCT06294548
- Testing
- Valemetostat, Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
The high cancer related mortality has remained a significant issue of health care in Poland, Europe and worldwide. The decreasing incidence rate for carcinoma of the distal stomach and a marked trend of increasing incidence for…
- Trial name
- NCT01523015
- Testing
- preoperative chemo- and chemoradiotherapy, Surgical resection
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Lublin
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Lung Adenocarcinoma, EGFR Activating Mutation
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
To compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients gradually progressed from first-line EGFR-TKI treatment.
- Trial name
- NCT03544814
- Testing
- icotinib combined with pemetrexed plus cisplatin, first icotinib and then pemetrexed plus cisplatin
- Volunteers
- 99 people
- Sponsor
- Shanghai Chest Hospital
Hepatocellular Carcinoma
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is a primary liver cancer. It is the 6th most common malignancy and the 3rd killers of all tumors worldwide with an incidence of 626,000 new patients a year.
- Trial name
- NCT02729506
- Testing
- Transarterial Radioembolization, Transarterial Chemoembolization using drug-eluting beads
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- King Faisal Specialist Hospital & Research Center